Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 14/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 14/20 | 0.51 |
| ▸ | PDK3 | Q15120 | 14/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 14/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674388 | 1.00 | ESR2 (0.55) | ESR2KDM4EBRD4PDK1PDK2 | |
| SCHEMBL3899182 | 0.92 | ESR2 (0.61) | ESR2KDM4EBRD4PDK1PDK2 | |
| SCHEMBL1734404 | 0.89 | ESR2 (0.55) | ESR2KDM4EBRD4PDK1PDK2 | |
| SCHEMBL4948953 | 0.88 | NOTUM (0.55) | KDM4EBRD4MPOHSD17B10 | |
| SCHEMBL21428260 | 0.86 | KDM4E (0.73) | KDM4EBRD4PDK1PDK2PDK3 | |
| SCHEMBL18216843 | 0.85 | KDM4E (0.53) | KDM4EBRD4MPOHSD17B10 | |
| SCHEMBL6846584 | 0.85 | NR1H2 (0.56) | KDM4EBRD4PDK1PDK2PDK3 | |
| SCHEMBL31552767 | 0.85 | NOTUM (0.55) | KDM4EBRD4PDK1PDK2PDK3 | |
| SCHEMBL380901 | 0.85 | KDM4E (0.53) | KDM4EBRD4PDK1PDK2PDK3 | |
| SCHEMBL5781463 | 0.85 | KDM4E (0.53) | ESR2KDM4EBRD4PDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678634-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024183793-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | 上海海和药物研究开发股份有限公司 | 2024-09-12 | — | — | WO | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| CN-117177969-A | Compound with benzyloxy aryl ether structure, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-12-05 | — | — | CN | disclosed |
| EP-1358162-B1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1585731-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | AEBI JOHANNES (CH) | 2005-01-27 | — | — | US | disclosed |
| WO-2004026837-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| US-6706751-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | HOFFMAN-LA ROCHE INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1358162-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| WO-2002050041-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-27 | — | — | WO | disclosed |
| EP-1210343-A2 | BENZOIC ACID DERIVATIVES AND THEIR USE AS PPAR RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012187-A2 | BENZOIC ACID DERIVATIVES AND THEIR USE AS PPAR RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | ESR2 1445/4885KDM4E 4774/4885BRD4 4247/4885 |
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | ESR2 1642/4885KDM4E 3656/4885BRD4 1576/4885 |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | ESR2 1642/4885KDM4E 3656/4885BRD4 1576/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | ESR2 1537/4885KDM4E 4796/4885BRD4 4405/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | ESR2 1445/4885KDM4E 4774/4885BRD4 4247/4885 |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | PSMG3, MYCBP2, PSME2 | ESR2 3052/4885KDM4E 3925/4885BRD4 1892/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | ESR2 1445/4885KDM4E 4774/4885BRD4 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.